Rachel R. Bailey, MPH

home / authors / rachel-r-bailey-mph

Articles

March 10th 2011

Economic Model for Emergency Use Authorization of Intravenous Peramivir

Bruce Y. Lee, MD, MBA Julie H. Y. Tai, MD Rachel R. Bailey, MPH Sarah M. McGlone, MPH Ann E. Wiringa, MPH Shanta M. Zimmer, MD Kenneth J. Smith, MD, MS Richard K. Zimmerman, MD, MPH

The US Food and Drug Administration granted emergency use authorization of intravenous neuraminidase inhibitors for patients with 2009 influenza A (H1N1), creating a need for economic studies.

January 14th 2011

Economic Model for Emergency Use Authorization of Intravenous Peramivir

Bruce Y. Lee, MD, MBA Julie H. Y. Tai, MD Rachel R. Bailey, MPH Sarah M. McGlone, MPH Ann E. Wiringa, MPH Shanta M. Zimmer, MD Kenneth J. Smith, MD, MS Richard K. Zimmerman, MD, MPH

The US Food and Drug Administration granted emergency use authorization of intravenous neuraminidase inhibitors for patients with 2009 influenza A (H1N1), creating a need for economic studies.

July 13th 2010

Screening Cardiac Surgery Patients for MRSA: An Economic Computer Model

Bruce Y. Lee, MD, MBA Ann E. Wiringa, MPH Rachel R. Bailey, MPH Vishal Goyal, MPH G. Jonathan Lewis, DO, MPH Becky Y. K. Tsui, MPH Kenneth J. Smith, MD, MS Robert R. Muder, MD

Routine preoperative MRSA screening of cardiac surgery patients could provide substantial economic value to third-party payers and hospitals under a wide range of circumstances.

March 1st 2010

Economics of Influenza Vaccine Administration Timing for Children

Bruce Y. Lee, MD, MBA Julie H. Y. Tai, MD Rachel R. Bailey, MPH Kenneth J. Smith, MD, MS Andrew J. Nowalk, MD, PhD

Vaccinating children earlier (ie, September or October) can provide net economic benefit to society and to third-party payers. Vaccination of children remained cost-effective through December.